Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) was downgraded by equities research analysts at Wells Fargo & Company from an “outperform” rating to a “market perform” rating in a research note issued on Thursday.

A number of other analysts also recently issued reports on ICPT. Wedbush reaffirmed an “outperform” rating and issued a $231.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, May 26th. ValuEngine raised Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Credit Suisse Group set a $201.00 price objective on Intercept Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, June 3rd. Cowen and Company reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Monday, June 12th. Finally, BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Intercept Pharmaceuticals has an average rating of “Buy” and a consensus target price of $203.86.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The business had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same quarter in the previous year, the company posted ($3.14) EPS. The company’s revenue was up 459.6% compared to the same quarter last year.

WARNING: “Intercept Pharmaceuticals, Inc. (ICPT) Rating Lowered to Market Perform at Wells Fargo & Company” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/09/21/intercept-pharmaceuticals-inc-icpt-rating-lowered-to-market-perform-at-wells-fargo-company.html.

In related news, CMO David Shapiro sold 1,250 shares of the business’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $117.43, for a total transaction of $146,787.50. Following the completion of the transaction, the chief marketing officer now owns 45,812 shares in the company, valued at approximately $5,379,703.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Lisa Bright sold 394 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $121.33, for a total value of $47,804.02. Following the transaction, the insider now owns 23,619 shares of the company’s stock, valued at approximately $2,865,693.27. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,013 shares of company stock valued at $6,198,747. 9.20% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. lifted its holdings in shares of Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 14 shares during the period. Public Employees Retirement Association of Colorado lifted its holdings in shares of Intercept Pharmaceuticals by 1.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 43 shares during the period. Janney Montgomery Scott LLC lifted its holdings in shares of Intercept Pharmaceuticals by 1.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after buying an additional 62 shares during the period. WFG Advisors LP lifted its holdings in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 125 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 132 shares during the period. Institutional investors and hedge funds own 82.19% of the company’s stock.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.